Trademark: 79288213
Word
CURIGIN
Status
Registered
Status Code
700
Status Date
Tuesday, December 14, 2021
Serial Number
79288213
Registration Number
6585328
Registration Date
Tuesday, December 14, 2021
Mark Type
4000
Filing Date
Tuesday, April 21, 2020
Published for Opposition
Tuesday, September 28, 2021

Trademark Owner History
Curigin Co., Ltd - Original Registrant

Classifications
5 Biopharmaceuticals for the prevention of cancer; biopharmaceuticals for the diagnosis of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals in the form of cancer oncolytic virus for the prevention of cancer; biopharmaceuticals in the form oncolytic virus for the diagnosis of cancer; biopharmaceuticals in the form of oncolytic virus for the treatment of cancer; Drugs for medical purpose for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; Veterinary preparations for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; anti-cancer preparations; antiulcerants; vaccines; pharmaceutical preparations and substances for the prevention of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical compounds for treating cancer; pharmaceuticals for viral and non-viral vector-based gene therapy; medicine for viral and non-viral vector-based gene therapy for human purposes; antibiotics; dietary supplements; dietetic nutritionally fortified food adapted for medical purposes; insecticides; fungicides
35 Providing commercial information and consumer product information; import-export agency services; sales agency services, namely, sales promotion for others in the field of apparatus for use in medical analysis; arranging sales events for others in the field of apparatus for use in medical analysis; sales agency services, namely, sales promotion for others in the field of pharmaceuticals; arranging sales events for others in the field of pharmaceuticals; business intermediary services in the nature of purchasing pharmaceuticals for others relating to mail order by telecommunications; procurement of contracts for the purchase and sale of goods and services; advertising services; advertising services relating to pharmaceutical products; business intermediary services in the nature of matching purchasers with sellers of goods and services for the sale and purchase of goods and services
44 Providing health information, not including dentistry; healthcare information services relating to the use of medical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; medical and pharmaceutical consultancy; consultancy services relating to pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases
42 Research relating to biotechnology; scientific research for medical purposes in the field of cancerous diseases; research relating to pharmaceuticals; research in the field of medical products; medical research services; conducting clinical trials for others; clinical studies in the nature of medical research; development of new technology for others in the field of biotechnology; scientific research for medical purposes in the area of cancerous diseases; development of medical products; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; conducting clinical research in the field of medicines; clinical trials of medicines, for others; software design and development; computer programming for others in the medical field

Trademark Events
May 25, 2022
Final Disposition Notice Sent To Ib
May 24, 2022
Final Disposition Processed
Mar 14, 2022
Final Disposition Notice Created, To Be Sent To Ib
Dec 19, 2021
Notification Of Possible Opposition - Processed By Ib
Dec 14, 2021
Registered-Principal Register
Dec 1, 2021
Notification Of Possible Opposition Sent To Ib
Dec 1, 2021
Notification Of Possible Opposition Created, To Be Sent To Ib
Oct 25, 2021
Notification Processed By Ib
Sep 28, 2021
Official Gazette Publication Confirmation E-Mailed
Sep 28, 2021
Published For Opposition
Sep 22, 2021
Notification Of Possible Opposition Sent To Ib
Sep 22, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Sep 8, 2021
Notification Of Notice Of Publication E-Mailed
Aug 25, 2021
Approved For Pub - Principal Register
Aug 25, 2021
Examiner's Amendment Entered
Aug 25, 2021
Notification Of Examiners Amendment E-Mailed
Aug 25, 2021
Examiners Amendment E-Mailed
Aug 25, 2021
Examiners Amendment -Written
Aug 9, 2021
Teas/Email Correspondence Entered
Aug 9, 2021
Correspondence Received In Law Office
Aug 9, 2021
Teas Request For Reconsideration Received
Apr 8, 2021
Notification Of Final Refusal Emailed
Apr 8, 2021
Final Refusal E-Mailed
Apr 8, 2021
Final Refusal Written
Feb 25, 2021
Teas/Email Correspondence Entered
Feb 25, 2021
Correspondence Received In Law Office
Feb 25, 2021
Teas Response To Office Action Received
Sep 27, 2020
Refusal Processed By Ib
Sep 5, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Aug 25, 2020
Refusal Processed By Mpu
Jul 19, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Jul 18, 2020
Non-Final Action Written
Jul 13, 2020
Assigned To Examiner
Jun 30, 2020
Application Filing Receipt Mailed
Jun 26, 2020
New Application Office Supplied Data Entered In Tram
Jun 25, 2020
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24